Slideset on: Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone.

Slides:

Advertisements

Similar presentations

Palumbo A et al. Proc ASH 2013;Abstract 536.

Advertisements

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Facon T et al. Proc ASH 2013;Abstract 2.

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

Novel AKT Inhibitor Afuresertib in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity.

1. 2 Lenalidomide in Newly Diagnosed Multiple Myeloma Clinical Update EHA 2010 DR. OUSSAMA JRADI.

Richardson PG et al. Proc ASH 2013;Abstract 535.

Palumbo A et al. Proc ASH 2012;Abstract 446.

Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma 1,2 The Cardiovascular Impact of Carfilzomib in Multiple Myeloma 3 1 Stewart.

Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Myeloma Updates ASH 2011 Annual Meeting Steve Smith OHSU Knight Cancer Institute Center for Hematologic Malignancies

Relapsed and Refractory Myeloma Case 2

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.

Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.

The Investigational Agent MLN9708, an Oral Proteasome Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma (MM): Results from the Expansion.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients with Previously.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.

A Phase Ib Dose Escalation Trial of SAR (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.

Palumbo A et al. Proc ASH 2014;Abstract 175.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Ruan J et al. Proc ASH 2013;Abstract 247.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.

Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma.

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory.

Slideset on: Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the.

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

Phase II Study: Pembrolizumab + Pomalidomide/Dexamethasone for Patients With R/R MM New Findings in Hematology: Independent Conference Coverage* of ASH.

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple.

New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida ARRAY : Phase II Trial of Carfilzomib.

New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida TOURMALINE-MM1: Improved PFS With Ixazomib.

CCO Independent Conference Highlights

IFM Phase II Study: KRd Induction and Consolidation Before Len Maintenance Highly Effective in Newly Diagnosed MM New Findings in Hematology: Independent.

Palumbo A et al. Proc ASH 2012;Abstract 200.

ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM

CCO Independent Conference Highlights

Attal M et al. Proc ASH 2010;Abstract 310.

Korde N et al. Proc ASH 2012;Abstract 732.

Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma

ELOQUENT-2: Addition of Elotuzumab to Len/Dex Extends PFS in Relapsed/Refractory Myeloma CCO Independent Conference Highlights of the 2015 ASCO Annual.

FORTE: Induction With Carfilzomib, Dexamethasone, and Cyclophosphamide or Lenalidomide in Newly Diagnosed MM CCO Independent Conference Highlights* of.

Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

New Findings in Hematology: Independent Conference Coverage

Phase II Study: Pembrolizumab Plus Pomalidomide and Dexamethasone Active in R/R Multiple Myeloma New Findings in Hematology: Independent Conference Coverage.

Mateos MV et al. Proc ASH 2013;Abstract 403.

Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation.

KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM CCO Independent Conference Coverage* of the 2016.

Phase Ib MMY1001: Daratumumab Plus Pom/Dex for Patients With R/R MM

Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation.

Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Niesvizky R et al. Proc ASH 2010;Abstract 619.

Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.

Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)1 Final Results from.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Presentation transcript:

Slideset on: Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120: Carfilzomib/Lenalidomide/Low-Dose Dexamethasone (CRd) Chemotherapy Active and Well Tolerated in Patients With Newly Diagnosed Multiple Myeloma This program is supported by educational grants from

clinicaloptions.com/oncology An Online Journal Club Resource for Physician Fellows 1. O’Connor OA, et al. Clin Cancer Res. 2009;15: Mohty B, et al. Haematologica. 2010;95: Vij R, et al. ASH Abstract 813. Background  Carfilzomib (PR-171): selective, irreversible proteasome inhibitor with activity in hematologic malignancies, including MM [1] –Durable antitumor activity in patients with relapsed/refractory multiple myeloma [1] –Active in patients refractory to bortezomib [2] –Decreased incidence of peripheral neuropathy compared with bortezomib [3]

clinicaloptions.com/oncology An Online Journal Club Resource for Physician Fellows Jakubowiak AJ, et al. Blood 2012;120: Phase I: CRd MTD Lenalidomide 25 mg/day on Days Dexamethasone 40 mg/wk for cycles 1-4, 20 mg/wk for cycles 5+ Carfilzomib 28-day cycles: Days 1, 2, 8, 9, 15, 16 for cycles 1-8 (induction); Days 1, 2, 15, 16 for cycles 9-24 (maintenance) All patients receive carfilzomib 20 mg/m 2 on Days 1, 2 for cycle 1, then proceed to investigational dose (remainder of study) Phase II: MTD not reached; dosing as before with carfilzomib 36 mg/m 2 Primary endpoint: response rate ≥ nCR; secondary endpoints: ORR, duration, PFS, OS, TTP, and feasibility of stem cell collection after cycle 4 ≤ 1 DLT ≥ 2 DLT MTD: 20 mg/m² 20 mg/m² MPD: 36 mg/m² 27 mg/m²36 mg/m² ≤ 1 DLT MTD: 27 mg/m² ≥ 2 DLT Phase I/II Study Design

clinicaloptions.com/oncology An Online Journal Club Resource for Physician Fellows ORR With CRd  Rapid, durable responses improve with continued treatment  Depth and rate of response not affected by ISS stage or cytogenetic profile  PFS: 97% (12 mos), 92% (24 mos) All Patients (N = 53) 4+ Cycles (n = 49) 8+ Cycles (n = 36) 12+ Cycles (n = 29) sCR = nCR = VGPR = PR Patients With ORR (%) Jakubowiak AJ, et al. Blood 2012;120:

clinicaloptions.com/oncology An Online Journal Club Resource for Physician Fellows CRd Impact on Stem Cell Collection  35 patients underwent stem cell collection after 4 cycles  28 patients used only growth factors; 7 patients used chemotherapy and growth factors  Collection unsuccessful in 1 patient (older than 70 yrs of age, collection attempted after 8 cycles)  Median number of CD34+ cells: 6.9 x 10 6 /kg (range: x 10 6 /kg) Jakubowiak AJ, et al. Blood 2012;120:

clinicaloptions.com/oncology An Online Journal Club Resource for Physician Fellows Safety of CRd Regimen  MTD not reached  31% of patients required CRd dose modification  No grade 3/4 adverse events during maintenance phase Treatment-Emergent Adverse Events During Induction, %Any GradeGrade 3/4 Nonhematologic  Hyperglycemia7223  Hypophosphatemia4525  Elevated liver function test288  Rash288  Peripheral neuropathy23*0  Pulmonary embolism66 Hematologic  Thrombocytopenia6817  Anemia6021  Neutropenia3017 *Peripheral neuropathy: 3 grade 2 events, 20 grade 1 events. Jakubowiak AJ, et al. Blood 2012;120:

clinicaloptions.com/oncology An Online Journal Club Resource for Physician Fellows CRd Summary  Carfilzomib combined with lenalidomide and low-dose dexamethasone produces rapid, durable responses in patients with newly diagnosed MM –Response improved with continued treatment –≥ sCR: 45% (4 cycles), 61% (8 cycles), 62% (12 cycles) –Well tolerated –No grade 3/4 neuropathy; manageable hematologic toxicity; hyperglycemia, hypophosphatemia, liver dysfunction, rash, edema, dyspnea, DVT/PE noted –No adverse effects on stem cell collection –Median number of CD34+ cells: 6.9 x 10 6 /kg (range: x 10 6 /kg) Jakubowiak AJ, et al. Blood 2012;120: